Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosfomycin→

Fosfomycin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23155-02-4
Molecular formula
C3H7O4P
Molecular weight
138.06 g/mol
Drug class
Phosphonic acid antibacterialMurA enzyme inhibitor
Mechanism of action
Inhibits UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an early enzyme in bacterial peptidoglycan synthesis, blocking cell-wall formation and producing bactericidal activity.
Indications / reported uses
  • Oral fosfomycin tromethamine: treatment of uncomplicated acute cystitis in women caused by susceptible organisms such as Escherichia coli and Enterococcus faecalis
  • Intravenous fosfomycin formulations, where authorised, are used for selected serious infections caused by susceptible bacteria; route-specific indications are not interchangeable

Sources: US DailyMed — Fosfomycin tromethamine · EMA — Fosfomycin-containing medicines · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fosfomycin Environmental Risk Assessment (ERA) (the Fosfomycin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.